AH-001
/ AnHorn Medicines
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 15, 2025
Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: AnHorn Medicines Co. Ltd.
New P1 trial • Alopecia • Dermatology • Immunology
1 to 1
Of
1
Go to page
1